GrayMatters Health Prism PTSD now offered as video game treatment in Conway SC — first FDA-cleared neurofeedback for PTSD reaching community clinics
Summary
GrayMatters Health's Prism for PTSD — the first FDA 510(k)-cleared self-neuromodulation device for PTSD, using EEG-fMRI amygdala biomarker neurofeedback — was reported in Neurotech Notables #51 as now being offered at a clinic in Conway, South Carolina as described in a WPDE news story headlined "The coolest thing: Cutting-edge video game PTSD treatment now offered in Conway." The Prism system uses a proprietary EEG-fMRI Pattern (EFP) biomarker from the patient's own brain imaging and combines it with real-time EEG feedback to train patients to lower their amygdala activity through mental strategy exploration during engaging audio-visual sessions. The Conway, South Carolina deployment demonstrates Prism reaching community mental health clinics outside major academic centers — the commercial scaling milestone that determines whether any PTSD device achieves meaningful population impact.
Why it matters
Prism for PTSD reaching a community clinic in Conway, South Carolina — a small city of 26,000 people — is more commercially significant than a Harvard or Johns Hopkins adoption. Academic medical centers adopt technologies quickly; community clinics adopt them when the value proposition is simple, the training is manageable, and reimbursement is workable. Conway is the proof that Prism has crossed into practical community clinic deployment, which is where the 12 million Americans with PTSD actually seek treatment.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial